{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:24:03Z","timestamp":1792193043480,"version":"4.4.0"},"reference-count":64,"publisher":"Wiley","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin\u2010assisted psychotherapy for patients with comorbid AUD and depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A prospective, single\u2010center, double\u2010blind, parallel (2:1), randomized controlled pilot study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study was conducted in a French inpatient addiction treatment program offering intensive relapse prevention interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>\n                      Of 350 screened patients, 30 adults (mean age 49\u2009\u00b1\u200910\u00a0years; 43% female) with severe AUD (\n                      <jats:italic>Diagnostic and Statistical Manual of Mental Disorders<\/jats:italic>\n                      , Fifth Edition [DSM\u20105] criteria) and a Beck Depression Inventory\u2010II (BDI\u2010II) score \u226514 were included. Participants had completed detoxification between 14 and 60\u2009days prior to inclusion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants received either two oral sessions of 25\u2009mg (n\u2009=\u200920) or 1\u00a0mg (n\u2009=\u200910) psilocybin\u2010assisted psychotherapy spaced three weeks apart, as an add\u2010on to standard care. Patients, investigators and outcome assessors were all blinded to patient group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>The primary outcome was feasibility, according to participation in both dosing sessions and recruitment\/inclusion rates. Secondary outcomes included alcohol use (Alcohol Timeline Followback), time to relapse, craving (Craving Experience Questionnaire), depression (BDI\u2010II), safety and blinding integrity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>One participant in the 25\u2009mg group could not receive the second dose due to myocardial infarction occurring three days earlier, unrelated to the treatment. Four participants in the control group refused the second session after guessing their group assignment (p\u2010value\u2009=\u20090.019), with one participant self\u2010administering 3,4\u2010Methylenedioxymethamphetamine (MDMA). At 12\u2009weeks, the 25\u2009mg group showed significantly greater abstinent rate (11\/20 (55%) vs 1\/9 (11%) (one lost of follow up) (difference\u2009=\u2009\u221244%, [95% confidence interval [CI]: \u221282% to \u22125.9%]), p\u2009=\u20090.043), reductions in % drinking days \u2212100 (\u2212100 to \u221249) vs\u2009\u2212\u200993 (\u221296 to 0), p\u2009=\u20090.038 and craving frequency \u22128 (\u221223 to \u22121) vs\u2009+\u20097 (\u22122 to 11), p\u2009=\u20090.045, respectively in the 25 vs 1\u00a0mg groups (median [25;75]). Relapse rates were 35% in the 25\u2009mg group and 50% in the control group (HR\u2009=\u20090.52 [0.16 to1.65]). No efficacy differences were observed based on antidepressant use in terms of drinking and depression. Blinding was imperfect (correct guess by patients: 93.3%; investigators: 86.7%). Twenty\u2010five adverse events were reported in 10 patients (50%) in the 25\u2009mg group versus 6 patients (60%) in the control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Psilocybin\u2010assisted psychotherapy appears feasible, acceptable, and safe in recently detoxified patients with comorbid alcohol use disorder and depression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/add.70152","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:40:42Z","timestamp":1753342842000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-442X","authenticated-orcid":false,"given":"Amandine","family":"Luquiens","sequence":"first","affiliation":[{"name":"University Montpellier, Department of Addiction, CHU N\u00eemes, N\u00eemes, France, CESP, University Paris\u2010Sud, UVSQ, INSERM Universit\u00e9 Paris\u2010Saclay  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahbia","family":"Belahda","sequence":"additional","affiliation":[{"name":"Department of Addiction CHU N\u00eemes, University Montpellier  N\u00eemes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Graux","sequence":"additional","affiliation":[{"name":"Department of Addiction CHU N\u00eemes, University Montpellier  N\u00eemes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noe","family":"Igounenc","sequence":"additional","affiliation":[{"name":"University Montpellier, Department of Addiction, CHU N\u00eemes, N\u00eemes, France, CESP, University Paris\u2010Sud, UVSQ, INSERM Universit\u00e9 Paris\u2010Saclay  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Serrand","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM) CHU N\u00eemes, University Montpellier  N\u00eemes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rochefort","sequence":"additional","affiliation":[{"name":"University Montpellier, Department of Addiction, CHU N\u00eemes, N\u00eemes, France, CESP, University Paris\u2010Sud, UVSQ, INSERM Universit\u00e9 Paris\u2010Saclay  Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mura","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM) CHU N\u00eemes, University Montpellier  N\u00eemes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sergent","sequence":"additional","affiliation":[{"name":"Department of Addiction CHU N\u00eemes, University Montpellier  N\u00eemes France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6930a1"},{"key":"e_1_2_11_3_1","first-page":"89","article-title":"La consommation d'alcool chez les adultes en France en 2017","volume":"5","author":"Ichard J","year":"2019","journal-title":"Bull Epidemiol Hebd"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.13.1689"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v42.1.01"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.0584"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0349.2012.00833.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14599"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.03.005"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2019.05.038"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRA.0000000000000522"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000083"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071560"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.05.006"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01101-3"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13229"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117725915"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524187113"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114565144"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251319457"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103149"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078084"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3618"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000574"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2024.11.022"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180730104707"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2011.00347.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14650"},{"key":"e_1_2_11_34_1","unstructured":"ThomasK.A playlist for psilocybin: Spotify.https:\/\/open.spotify.com\/playlist\/1usTotvTC5uBKcN4KI2yuE"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(96)01263-X"},{"key":"e_1_2_11_36_1","volume-title":"Assessing alcohol problems: a guide for clinicians and researchers","author":"Sobell LC"},{"key":"e_1_2_11_37_1","unstructured":"WHO.Alcohol heavy episodic drinking (population) past 30 days. Indicator metadata registry list 2025."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12472"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0865-7"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1190-5"},{"key":"e_1_2_11_41_1","volume-title":"Manual for the beck depression inventory\u2010II","author":"Beck A","year":"1996"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2011.12.003"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-6185(92)90026-4"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOBA.0000007455.08539.94"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1037\/pas0001109"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-8624.1998.tb06161.x"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chiabu.2021.105201"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-3797(98)00017-8"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2008.12.006"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/jts.22059"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979351"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2024.04.001"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/nur.20247"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.887255"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06585-x"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01648-7"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.241191"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241237870"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-024-00321-2"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0085"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dym020"},{"key":"e_1_2_11_63_1","unstructured":"EMA.EMA multi\u2010stakeholder workshop on psychedelics. 2024 16\u201317 April2024."},{"key":"e_1_2_11_64_1","unstructured":"FDA.Psychedelic drugs: Considerations for clinical investigations202306\/26\/2023. Contract No.: FDA\u20102023\u2010D\u20101987."},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.14530"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.70152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:38:03Z","timestamp":1760416683000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.70152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":64,"alternative-id":["10.1111\/add.70152"],"URL":"https:\/\/doi.org\/10.1111\/add.70152","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"add.70152"}}